Scholarlink

Background <p>This umbrella meta-analysis evaluates the effects of probiotics on cognitive function and metabolic health in Alzheimer’s disease (AD) and mild cognitive impairment (MCI) by synthesizing findings from meta-analyses of randomized controlled trials (RCTs), as existing evidence remains inconclusive.</p> Methods <p>A systematic search was conducted in PubMed, Web of Science, and Scopus to identify meta-analyses of RCTs investigating the impact of probiotic supplementation on cognitive function and metabolic biomarkers. The random-effects model was used. Heterogeneity and publication bias were assessed.</p> Results <p>Thirteen meta-analyses, comprising 3910 patients, were included. Probiotics significantly improved cognitive function in AD (SMD = 0.78, 95% CI: 0.33 to 1.23) and MCI (SMD = 0.43, 95% CI: 0.15 to 0.70). Probiotics also increased total antioxidant capacity (SMD = 0.40, 95% CI: 0.11 to 0.70) and reduced MDA (SMD =  − 0.35, 95% CI: − 0.62 to − 0.09) and hs-CRP (SMD =  − 0.59, 95% CI: − 0.87 to − 0.30). Insulin resistance improved, as reflected by decreased HOMA-IR (SMD =  − 0.34, 95% CI: − 0.43 to − 0.26). No significant effects were observed on glutathione, nitric oxide, or lipid profiles.</p> Conclusion <p>Probiotic supplementation appears to enhance cognitive function and metabolic parameters in individuals with MCI and AD, likely through mechanisms involving inflammation reduction, oxidative stress modulation, and improved insulin sensitivity. Further high-quality RCTs are required to validate these findings and determine optimal probiotic formulations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of probiotics on cognitive function and cardiovascular risk factors in mild cognitive impairment and Alzheimer’s disease: an umbrella meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月8日

查看全文
  • Bin Xiao,
  • Lina Fu,
  • Zhe Yang,
  • Guran Yu

摘要

Background

This umbrella meta-analysis evaluates the effects of probiotics on cognitive function and metabolic health in Alzheimer’s disease (AD) and mild cognitive impairment (MCI) by synthesizing findings from meta-analyses of randomized controlled trials (RCTs), as existing evidence remains inconclusive.

Methods

A systematic search was conducted in PubMed, Web of Science, and Scopus to identify meta-analyses of RCTs investigating the impact of probiotic supplementation on cognitive function and metabolic biomarkers. The random-effects model was used. Heterogeneity and publication bias were assessed.

Results

Thirteen meta-analyses, comprising 3910 patients, were included. Probiotics significantly improved cognitive function in AD (SMD = 0.78, 95% CI: 0.33 to 1.23) and MCI (SMD = 0.43, 95% CI: 0.15 to 0.70). Probiotics also increased total antioxidant capacity (SMD = 0.40, 95% CI: 0.11 to 0.70) and reduced MDA (SMD =  − 0.35, 95% CI: − 0.62 to − 0.09) and hs-CRP (SMD =  − 0.59, 95% CI: − 0.87 to − 0.30). Insulin resistance improved, as reflected by decreased HOMA-IR (SMD =  − 0.34, 95% CI: − 0.43 to − 0.26). No significant effects were observed on glutathione, nitric oxide, or lipid profiles.

Conclusion

Probiotic supplementation appears to enhance cognitive function and metabolic parameters in individuals with MCI and AD, likely through mechanisms involving inflammation reduction, oxidative stress modulation, and improved insulin sensitivity. Further high-quality RCTs are required to validate these findings and determine optimal probiotic formulations.